-+ 0.00%
-+ 0.00%
-+ 0.00%
Racura Oncology's seamless phase 2b/3 Emili trial for recurrent or refractory acute myeloid leukemia received initial center approval.
Share
Listen to the news
Racura Oncology's seamless phase 2b/3 Emili trial for recurrent or refractory acute myeloid leukemia received initial center approval.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending